Skip to main navigation
Skip to main content

Utility Nav Header

  • Contact
  • Twitter
  • LinkedIn

Main navigation

  • About
    • Our Focus
    • CEO Video
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Responsibility
      • Corporate Governance
      • Diversity & Inclusion
      • Corporate Giving
  • Our Science
    • Our Approach
    • Pipeline
      • Pipeline
      • Repotrectinib
      • Elzovantinib (TPX-0022)
      • TPX-0046
      • TPX-0131
      • TPX-4589
    • Publications & Presentations
  • Clinical Trials
    • Company Trials
    • Compassionate Use
    • Investigator Sponsored Research
  • Investors
    • Overview
    • Press Releases
    • Events
    • Presentations
    • SEC Filings
    • Quarterly Results
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Leadership
      • Committee Composition
    • Investor Contact
    • Email Alerts
  • Careers
    • Vision, Mission & Values
    • Our Culture
    • Diversity & Inclusion
    • Opportunities
    • Our Hiring Process
    • Benefits

Documents & Charters

Governance Documents
Code of Business Conduct and Ethics
Stockholder Communications Process
Open Door Policy (Whistleblower)
Committee Charters
Audit Committee Charter
Corporate Strategy Committee Charter
Compensation Committee Charter
Nominating and Corporate Governance Committee Charter
Copyright © 2022 Turning Point Therapeutics, Inc. | All Rights Reserved | Sitemap | Terms of Use | Privacy Policy Statement